Literature DB >> 30697586

Episodic ataxia in CASPR2 autoimmunity.

A Sebastian López Chiriboga1, Sean Pittock1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30697586      PMCID: PMC6340329          DOI: 10.1212/NXI.0000000000000536

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
A 64-year-old man developed cognitive dysfunction and generalized seizures, followed by episodes of transient speech and gait disturbances lasting several minutes, occurring multiple times per day; the events were not associated with any triggers. Neurologic examination during one of his episodic symptoms (video 1) showed transient ataxic dysarthria. Testing for neural autoantibodies revealed evidence of voltage-gated potassium channel complex antibodies by radioimmunoprecipitation assay; CASPR2-IgG was positive in serum and CSF by cell-based assay. Brain MRI was normal; CSF analysis showed an elevated protein level at 101 mg/dL, but it was otherwise normal. Oncologic evaluation was negative. The cognitive symptoms improved; seizures and episodic ataxia resolved after 12 weeks of treatment with IV methylprednisolone. Episodic ataxia is a manifestation of CASPR2 autoimmunity;[1] patients can have normal MRI, and immunotherapy is beneficial. Neurologic examination of the patient showing transient ataxic dysarthria.Download Supplementary Video 1 via http://dx.doi.org/10.1212/000536_Video_1
  1 in total

1.  Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis.

Authors:  Bastien Joubert; Florent Gobert; Laure Thomas; Margaux Saint-Martin; Virginie Desestret; Philippe Convers; Véronique Rogemond; Géraldine Picard; François Ducray; Dimitri Psimaras; Jean-Christophe Antoine; Jean-Yves Delattre; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-14
  1 in total
  2 in total

Review 1.  Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.

Authors:  Giacomo Garone; Alessandro Capuano; Lorena Travaglini; Federica Graziola; Fabrizia Stregapede; Ginevra Zanni; Federico Vigevano; Enrico Bertini; Francesco Nicita
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

2.  Rectifying neurologic diagnosis through autoantibodies.

Authors:  Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-02-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.